---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-095366"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:04:14.894124+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA issues Complete Response Letter for Fortress Biotech's CUTX-101 over manufacturing issues

## Summary
- FDA issued CRL for CUTX-101 NDA to treat Menkes disease; cGMP deficiencies at the manufacturing facility.
- No efficacy/safety deficiencies cited; CRL solely based on manufacturing observations at the facility.
- Partner Sentynl expects to request FDA meeting and pursue resubmission promptly after facility's recent response.
- Cyprium eligible for up to $129M in milestones plus a Rare Pediatric Disease PRV upon NDA approval.
- NDA initially granted Priority Review; early treatment showed significant survival improvement in trials.

## SEC filing metadata
- accession: 0001104659-25-095366
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465925095366/0001104659-25-095366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465925095366/fbio-20251001x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-095366
- JSON: https://secwatch.observer/filing/0001104659-25-095366.json
- Plain text: https://secwatch.observer/filing/0001104659-25-095366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.